Advertisement PSI CRO further strengthens capabilities in infectious diseases clinical trials - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

PSI CRO further strengthens capabilities in infectious diseases clinical trials

PSI CRO, a full-service contract research organization, has announced that they are strengthening their clinical trial management approaches in the area of Infectious Diseases.

A therapeutically aligned infectious diseases team will support all ID studies at PSI, focused to provide optimized approaches to patient enrollment. The team will include staff from various departments including Feasibility, Medical Affairs and Project Management.

PSI has continued to grow their Infectious Diseases experience that includes new and ongoing global studies in pneumonias, complicated urinary tract infections, intra-abdominal infections, skin infections, sepsis, and other indications.

In the recent weeks, PSI reached an interim enrollment objective of several hundred patients in a global community acquired pneumonia trial, completed a global trial in a complicated urinary tract infection trial, fully enrolled a Phase III intra-abdominal infection study, as well as a trial of an influenza vaccine.

PSI will be represented at ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy) at Booth 514 that will be held in Washington D.C. on Saturday, September 6th through Monday, September 8th at the Walter E. Washington Convention Center.